TCR-alpha/beta and CD19-cell-depleted haploidentical stem cell therapy (Miltenyi Biotec)

N/A

Report date: 2024/12/23 15:40:37

Base Information

Drug NameTCR-alpha/beta and CD19-cell-depleted haploidentical stem cell therapy (Miltenyi Biotec)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsHematologic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaN/A
Originator CompaniesMiltenyi Biotec
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Children'S Hospital TuebingenMiltenyi BiotecSt. Jude Children'S Research Hospital
Inactive CompaniesN/A
Active IndicationsHematologic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A